Abstract
Forty subjects identified as dyslipidemic were assigned randomly to either soy powder (Soy) or red bean powder (Placebo). The soy group received daily a sachet of 18.1 g soy power containing 85 K cal and the placebo group received daily placebo sachet (23.1 g) of red bean powder containing 85.5 K cal in addition to the usual diet for four weeks. Intake of soy/placebo powder was assessed by measurement of 24-hour urinary isoflavone excretions at baseline and at the end of the intervention period. Relative to placebo, soy powder has significant effect over some Cardiovascular Disease (CVD) markers and Metabolic Syndrome (MetS) indices including abdominal circumference, triglycerides, HbA1c and insulin. These data support that the dietary consumption of soy has the property to reduce risk factors for CVD and MetS.
Highlights
Dyslipidemia and obesity are emerging as a major public health challenge in South Asian countries
Elevated levels of Very Low Density Lipoprotein (VLDL), and Low Density Lipoprotein (LDL) with reduction of High Density Lipoprotein (HDL) seen in patients with Metabolic Syndrome (MetS) contribute to atherogenic dyslipedemia
There was no significant change in systolic blood pressure (SBP), diastolic blood pressure (DBP) and Heart Rate (HR) in the soy group and in the placebo group
Summary
Dyslipidemia and obesity are emerging as a major public health challenge in South Asian countries. There is greater accumulation of fat at “ectopic” sites, namely the liver and the skeletal muscles. This feature leads to higher magnitude of insulin resistance, and its concomitant metabolic disorders (the metabolic syndrome) including atherogenic dyslipidemia. Metabolic Syndrome (MetS) is a plausible precondition for type II diabetes and Cardiovascular Diseases (CVD). MetS is characterised by symptoms of obesity, insulin resistance, hypertension, dyslipidemia and diabetes mellitus. Elevated levels of Very Low Density Lipoprotein (VLDL), and Low Density Lipoprotein (LDL) with reduction of High Density Lipoprotein (HDL) seen in patients with MetS contribute to atherogenic dyslipedemia. MetS and its components are associated with increased risk of stroke and CVD
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
